Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science



Rating:

Share or cite this content

Citations should be made in the following way:
S. Byrne, D. Jeffrey, R. Hatley (Chichester, United Kingdom). Effect of I:E ratio on delivery of colistimethate sodium from breath-enhanced and breath-activated nebulizers. Eur Respir J 2013; 42: Suppl. 57, 2117

Member's Comments

No comment yet.

Related content which might interest you: Delivery of dornase alfa via breath-actuated nebulizer: In-vitro measures of performance Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Pharmacokinetics of tobramycin nebulizer solution (300mg/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 Delivered dose of colistimethate sodium via 3 nebulizers; a comparison of bioassay and HPLC assay results Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI) Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics Source: International Congress 2016 – Paediatric asthma: recurrent, persistent, or severe obstruction and lung function techniques Year: 2016 Effect of high dose tobramicin (TOBI®) inhalation on respiratory values in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 503s Year: 2003 Effect of antistatic AeroChamber Plus® Flow-Vu® spacer on the systemic bioavailability of CHF5993 a novel triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis Source: Eur Respir Rev 2013; 22: 476-486 Year: 2013 Study of adherence to the use of inhaled sodium colistimethate through the I-neb® nebulization system Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014 Delivery efficiency of electronic and jet nebulisers aerosolising a colistimethate sodium solution Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 Nebulised antibiotics with the I-neb adaptive aerosol delivery (AAD) system: Impact on adherence in cystic fibrosis (CF) patients Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation Source: Eur Respir J 2011; 38: 1328-1335 Year: 2011 Effect of device and formulation on delivery of budesonide suspensions by nebulizers Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002 Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Effect of 3 different nebulisers on the aerosol delivery performance of isotonic disodium comoglycate (IsoCROM) Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006 Effects of dornase alfa and hypertonic saline on gas mixing in lung periphery in children with cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 In-vitro nebulised dose emission characteristics of a tobramycin solution (75mg/ml) using an I-Neb (I-NEB) and a pari LC+ driven by a TurboBoy compressor (PARI) nebuliser Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Effect of I:E ratio on the respirable delivered dose from nebulizers Source: Virtual Congress 2020 – Experimental and laboratory studies in intensive care unit medicine Year: 2020